ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Acadia Pharma (ACAD) Tops Q3 EPS by 11c
October 30, 2019 4:27 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.29), $0.11 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $94.6 million versus the consensus estimate of $88.49 million.
We took a major step forward in fulfilling our mission to improve the lives of... More
